GC Green Cross participated in an event organized by the Korea Disease Control and Prevention Agency (KDCA) to present the current status and future plans for its COVID-19 messenger ribonucleic acid (mRNA) vaccine development.
On August 12, GC Green Cross shared updates on its COVID-19 mRNA vaccine during a press academy event titled 'Current Status and Plans for Domestic mRNA Vaccine Technology Development' held at Korea University Guro Hospital.
This event, hosted by the KDCA, aimed to highlight the necessity of developing mRNA vaccines as a key technology for rapid response to future pandemics and to showcase domestic research achievements in mRNA vaccine development. The mRNA vaccine platform is recognized as a versatile technology capable of responding swiftly to new pathogens and variants.
GC Green Cross is the only domestic company undertaking a government-led project aimed at securing a domestic COVID-19 mRNA vaccine by 2028. The company confirmed safety, tolerability, and immunogenicity in the interim results of its Phase 1 clinical trial and submitted an Investigational New Drug (IND) application for Phase 2 clinical trials last month.
To support the development of its COVID-19 mRNA vaccine, GC Green Cross has dedicated over 100 personnel to research and development (R&D), production, and quality management (QM). The company has established a Good Manufacturing Practice (GMP) facility for mRNA production at its facility in Hwaseong, enabling it to conduct the entire process from research and development to production in-house.
GC Green Cross plans to obtain IND approval for Phase 2 clinical trials within this year, submit an IND for Phase 3 trials next year, and aims to apply for product approval in 2028.
Jung Jae-wook, head of R&D at GC Green Cross, stated, "The achievements so far are the result of the synergy between the government's rapid support system and GC Green Cross's development capabilities. We will continue to work closely with health authorities, including the KDCA, to secure global-level mRNA vaccine sovereignty."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.